Workflow
思摩尔国际:全球政策逆风期结束,雾化科技平台迎接新成长

Investment Rating - The report maintains a "Buy" rating for Smoore International with a target price of HKD 13.35, based on a 2025 PE of 48x [1] Core Investment Thesis - Smoore International has experienced a "double whammy" since 2021 due to regulatory headwinds in China and illegal product competition overseas, leading to declining EPS and profitability [1][5] - The company's core advantages remain strong, including leading R&D capabilities, deep customer relationships, and PMTA-approved products in the US [1][6] - Regulatory headwinds in the US and Europe are expected to ease, benefiting Smoore's pod and open-system vape businesses [1][9] - The launch of HNB products by major customers like BAT could create a second growth curve for Smoore [1][13] - Smoore's platform-based advantages in vaporization technology are expected to open new growth opportunities in medical and beauty vaporization [1][14] Market Opportunities US Market - The US illegal vape market accounts for over 70% of the market share, but regulatory crackdowns and potential relaxation of flavor restrictions could drive growth in the legal pod market [1][11] - The mid-term market size for legal pod systems in the US is expected to grow by 63%-299% compared to 2023 levels [1] - FDA has approved menthol-flavored vapes for the first time, signaling a potential easing of flavor restrictions [126] European Market - European countries are gradually implementing bans on disposable vapes, which could benefit Smoore's pod and open-system products [1][12] - The mid-term market size for pod systems in Europe is expected to grow by 42%-60%, while open-system products could grow by 52%-75% compared to 2023 levels [1] HNB Market - The global HNB market reached 34.1billionin2023,withaCAGRof23.134.1 billion in 2023, with a CAGR of 23.1% from 2018-2023 [1][13] - Smoore's major customer BAT is launching a breakthrough HNB product, Glo Hilo, in 2025, which could drive significant growth [1][13][159] Financial Performance - Revenue declined by 11.71% in 2022 and 8.04% in 2023, but is expected to grow by 7.8% in 2024 and 21.21% in 2026 [3] - Net profit attributable to shareholders dropped by 52.52% in 2022 and 34.47% in 2023, but is projected to grow by 43.02% in 2026 [3] - EPS is forecasted to be RMB 0.22, 0.26, and 0.37 for 2024-2026, respectively [1] R&D and Innovation - Smoore has maintained high R&D investment, with R&D expenses reaching RMB 1.483 billion in 2023, a 435% increase from 2019 [92] - The company has accumulated 7,695 patents globally, including 3,867 invention patents [92] - Smoore has developed new technologies like FEELM Turbo and POWER ALPHA 2.0, maintaining its leadership in core vaporization technologies [92] New Business Opportunities Medical Vaporization - Smoore has developed the Air Smooth medical mesh nebulizer system, which reduces drug waste by 60% [166] - The global pulmonary drug delivery device market is expected to grow from 60.1 billion in 2023 to $99.5 billion by 2031 [166] Beauty Vaporization - Smoore has launched its own beauty vaporization brand, MOYAL, targeting the mid-to-high-end market [165] Special Vaporization - Smoore's CCELL ceramic core technology has gained significant market share in the US special vaporization market [164]